Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.35 |
| ▸ | SYK | P43405 | 2/20 | 0.35 |
| ▸ | BTK | Q06187 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | TRIP13 | Q15645 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30748735 | 0.89 | AOC3 (0.36) | TRPV1MAPTLRRK2SYKBTK | |
| SCHEMBL30748916 | 0.88 | HDAC6 (0.34) | TRPV1MAPTSYKKCNH2JAK2 | |
| SCHEMBL30749137 | 0.87 | TRPV1 (0.35) | TRPV1MAPTLRRK2SYKBTK | |
| SCHEMBL30748787 | 0.85 | L3MBTL1 (0.36) | TRPV1MAPTLRRK2SYKJAK2 | |
| SCHEMBL30748939 | 0.85 | TRPV1 (0.33) | TRPV1MAPTLRRK2BTKKCNH2 | |
| SCHEMBL30749022 | 0.83 | AOC3 (0.34) | TRPV1MAPTSYKBTKKCNH2 | |
| SCHEMBL30748728 | 0.81 | BTK (0.35) | TRPV1MAPTLRRK2SYKBTK | |
| SCHEMBL30748831 | 0.78 | HRH3 (0.36) | KCNH2ALDH1A1 | |
| SCHEMBL31691334 | 0.78 | HDAC6 (0.34) | TRPV1MAPTSYKJAK2ALDH1A1 | |
| SCHEMBL30748781 | 0.77 | AOC3 (0.39) | TRPV1MAPTSYKBTKKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| EP-4565588-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | Suzhou Keen Therapeutics Co., Ltd. (CN) | 2025-06-11 | — | — | EP | disclosed |
| WO-2023241620-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | VHL, BRCA1, TERT | TRPV1 1952/4885MAPT 3029/4885LRRK2 4090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.